Author(s): B. Venkateswara Rao1, T. B. Patrudu, R. Uma Devi, Tentu Nageswara Rao

Email(s): patrudupath@gmail.com

DOI: 10.52711/0974-360X.2023.00680   

Address: B. Venkateswara Rao1, T. B. Patrudu1*, R. Uma Devi1, Tentu Nageswara Rao2
1Department of Chemistry, GITAM University, Hyderabad Campus, Telangana, India.
2Department of Chemistry, Krishna University, Machilipatnam, A.P., India.
*Corresponding Author

Published In:   Volume - 16,      Issue - 9,     Year - 2023


ABSTRACT:
Ambrisentan, an endothelin receptor antagonist, is subjected to forced degradation under neutral hydrolytic conditions, leading to a potential unknown impurity. This neutral degradation product (DP) has been detected using reverse-phase ultra-performance liquid chromatography (UPLC), where it has eluted at 1.24 relative retention time to the Ambrisentan peak. DP was isolated using semi-preparative HPLC from the degradation mixture. Later, the structure of DP was elucidated using high-resolution mass spectrometry, 2D Nuclear magnetic resonance spectroscopy (NMR), and Fourier transformed infrared spectroscopy (FTIR) spectroscopic techniques and characterized as 2-(2,2- diphenylvinyloxy)-4,6-dimethylpyrimidine.


Cite this article:
B. Venkateswara Rao1, T. B. Patrudu, R. Uma Devi, Tentu Nageswara Rao. Isolation and Structural Characterization of a major degradation product of Ambrisentan using Q-TOF-MS, NMR and FTIR. Research Journal of Pharmacy and Technology 2023; 16(9):4151-4. doi: 10.52711/0974-360X.2023.00680

Cite(Electronic):
B. Venkateswara Rao1, T. B. Patrudu, R. Uma Devi, Tentu Nageswara Rao. Isolation and Structural Characterization of a major degradation product of Ambrisentan using Q-TOF-MS, NMR and FTIR. Research Journal of Pharmacy and Technology 2023; 16(9):4151-4. doi: 10.52711/0974-360X.2023.00680   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-24


REFERENCES:
1.    Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43: S5–12
2.    Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 ; 131(6): 1917–28
3.    Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy. 2008; 9(1): 65–81
4.    WHO. The Global Alliance against Chronic Respiratory Diseases. Pulmonary hypertension [Accessed 2008 Jul 2]
5.    Galié, N.; Barberá, J.A.; Frost, A.; Ghofrani, H.; Hoeper, M.M.; McLaughlin, V.; Peacock, A.; Simonneau, G.; Vachiery, J.; Grunig, E.; Oudiz, R.; Vonk-Noordegraaf, A.; White, R.; Blair,C.; Gillies, H.; Miller, K.; Harris, J.; Langley, J.; Rubin, L. Inicial use of ambrisentanplustadalafil in pulmonary arterial hypertension. N. Engl. J. Med., 2015, 373, 834-844
6.    Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J.  2004; 25(24): 2243–78
7.    WD Feng, SM Zhuo, FL Zhang. Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan. Journal of Pharmaceutical and Biomedical Ana. 2019.
8.    R. Nirogi, V. Kandikere, P. Komarneni, R. Aleti, N. S. P. Padala and I. Kalaikadhiban. LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. Biomed. Chromatogr., 2012, 26, 1150.
9.    Nageswara Rao Ramisetti and Ramakrishna Kuntamukkala; LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method. New J. Chem. 2014; 38: 3050-3061
10.    Rodolfo Ortigara, Martin Steppe and Cássia Virginia Garcia. Stability-indicating UPLC-PDA Method for Ambrisentan Tablets and Identification of a Main Degradation Product by UPLC-MS/MS.
11.    Nanjappan Satheeshkumar, Gandham Naveenkumar. A Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography Method for Ambrisentan: An Endothelin Receptor Antagonist. Journal of Chromatographic Science. 2014; 52(8): 894–898,
12.    Mukthinuthalapati Mathrusri Annapurna, Bukkapatnam Venkatesh, Angirekula Narendra. Forced Degradation Studies of Agomelatine: Development and Validation of Stability Indicating RP-HPLC Method using Internal Standard. Research J. Pharm. and Tech. 2017; 10(3): 703-707. doi: 10.5958/0974-360X.2017.00132.9
13.    Akhilesh Gupta, Jaydeep Singh Yadav, Swati Rawat ,Mayuri Gandhi. Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS. Asian J. Pharm. Ana. 1(1): Jan.-Mar. 2011; Page 14-18.
14.    KasadPinaz A., K.S. Muralikrishna. Method Development and Acid Degradation Study of Rivaroxaban by RP-HPLC in bulk. Asian J. Pharm. Ana. 2013; 3(2): 62-65.
15.    Tentu Nageswara Rao, Muralidhar Reddy Avuthu, B. Venkata Reddy, SNVS Murthy. Forced degradation study of TerbinafineHCl by HPLC with PDA detector. Asian J. Research Chem. 2016; 9(11): 561-565. doi: 10.5958/0974-4150.2016.00076.6.
16.    Tentu Nageswara Rao, Imad Hussain, Y. Prashanthi, T. B. Patrudu. Forced Degradation Study for Tolterodine by HPLC with PDA Detection. Asian J. Pharm. Ana. 2019; 9(2):77-81. doi: 10.5958/2231-5675.2019.00015.2


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available